Recombinant Soluble CD59 for Retinal Protection in AMD
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for age-related macular degeneration (AMD) are inadequate, particularly for wet AMD, which does not have a cure, and advanced dry AMD lacks effective treatment options, with existing therapies for wet AMD only slowing progression and no known treatments for advanced dry AMD, and there is a need for methods to assay and treat AMD effectively.
Innovation Solution
A pharmaceutical composition comprising a recombinant soluble CD59 (rsCD59) protein, formulated for ocular delivery using viral vectors like adenovirus, adeno-associated virus, or herpesvirus, to protect retinal pigment epithelial cells from human membrane attack complex deposition, thereby treating AMD.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If laser surgery, photodynamic therapy, or injections are used to treat wet AMD, then progression of the disease is slowed, but the disease is not cured and central vision loss continues
Solution Approach 1:
The patent introduces recombinant soluble CD59 (rsCD59) as an intermediary substance that specifically blocks the complement membrane attack complex (MAC) from damaging retinal cells. This mediator provides direct cellular protection without the side effects of existing treatments, addressing the insufficiency of current therapies in preserving vision while controlling disease progression.
Solution Approach 2:
The invention extracts and utilizes the protective function of the CD59 protein, which naturally inhibits MAC formation, and delivers it directly to the eye through ocular administration. This extraction of the specific protective mechanism allows targeted treatment that addresses the root cause of cell damage in AMD without relying on non-specific anti-inflammatory or anti-VEGF approaches.
2Object-affected harmful factors
If mouse CD59 fusion protein is administered to reduce choroidal neovascularization symptoms, then some protective effect is achieved, but efficacy is unclear and human administration may cause side effects
Solution Approach 1:
The patent changes the source parameter of the CD59 protein from murine to human, creating a recombinant human soluble CD59 that is immunologically compatible with human patients. This parameter change eliminates the risk of immune reactions associated with mouse protein administration while maintaining the protective anti-MAC function, thereby improving treatment safety and reliability for human AMD patients.
3Reliability
If high-dose antioxidants and zinc are used to prevent intermediate AMD progression, then progression to advanced AMD is prevented, but no treatment exists for advanced dry AMD
Solution Approach 1:
The patent creates a universal treatment approach using rsCD59 that can be applied across multiple AMD stages and types (both wet and dry AMD). The mechanism of blocking MAC formation is fundamentally protective and applicable regardless of disease stage, providing a versatile therapy that addresses both prevention and treatment needs, unlike antioxidants which only work in intermediate stages.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively reduces cell lysis and MAC deposition, providing protection to retinal cells and potentially halting or reversing AMD progression by using a genetically engineered CD59 protein for targeted ocular delivery.
Implementation Method 1
CD59 is a membrane-bound glycoprotein that inhibits assembly of functional MACs and thus protects cells from complement-mediated activation and/or lysis
Implementation Method 2
local expression of exogenously delivered human complement regulatory protein CD59 was found to protect the RPE from human MAC deposition in vivo
Implementation Method 3
A source of the rsCD59 protein is a viral vector having a genetically engineered genome derived from: adenovirus, adeno-associated virus, herpesvirus, or a lentivirus
Data Source
Figure 1A~1B
Figure 1C
Figure 2A~2B
AI summary
Methods and compositions for treating a subject having age-related macular degeneration (AMD), methods of assaying human macular degeneration (MD), and methods and kits for assaying potential therapeutic agents for treatment of human MD are provided herein.